Identification of an N-terminal 27 kDa fragment of Mycoplasma pneumoniae P116 protein as specific immunogen in M. pneumoniae infections by Tabassum, Irum et al.
RESEARCH ARTICLE Open Access
Identification of an N-terminal 27 kDa fragment
of Mycoplasma pneumoniae P116 protein as
specific immunogen in M. pneumoniae infections
Irum Tabassum
1, Rama Chaudhry
1*, Bishwanath Kumar Chourasia
1, Pawan Malhotra
2
Abstract
Background: Mycoplasma pneumoniae is an important cause of respiratory tract infection and is increasingly being
associated with other diseases such as asthma and extra-pulmonary complications. Considerable cross-reactivity is
known to exist between the whole cell antigens used in the commercial serological testing assays. Identification of
specific antigens is important to eliminate the risk of cross-reactions among different related organisms. Adherence
of M. pneumoniae to human epithelial cells is mediated through a well defined apical organelle to which a
number of proteins such as P1, P30, P116 and HMW1-3 have been localized, and are being investigated for
adhesion, gliding and immunodiagnostic purposes.
Methods: A 609 bp fragment P116(N-27), corresponding to the N-terminal region of M. pneumoniae P116 gene was
cloned and expressed. A C-terminal fragment P1(C-40), of P1 protein of M. pneumoniae was also expressed. Three
IgM ELISA assays based on P116(N-27), P1(C-40) and (P116 (N-27) +P 1 (C-40)) proteins were optimized and a detailed
analysis comparing the reactivity of these proteins with a commercial kit was carried out. Comparative statistical
analysis of these assays was performed with the SPSS version 15.0.
Results: The expressed P116(N-27) protein was well recognized by the patient sera and was immunogenic in rabbit.
P1(C-40) of M. pneumoniae was also immunogenic in rabbit. In comparison to the reference kit, which is reported to
be 100% sensitive and 75% specific, ELISA assay based on purified P116(N-27), P1(C-40) and (P116(N-27) +P 1 (C-40))
proteins showed 90.3%, 87.1% and 96.8% sensitivity and 87.0%, 87.1% and 90.3% specificity respectively. The p value
for all the three assays was found to be < 0.001, and there was a good correlation and association between them.
Conclusion: This study shows that an N-terminal fragment of P116 protein holds a promise for serodiagnosis of M.
pneumoniae infection. The IgM ELISA assays based on the recombinant proteins seem to be suitable for the use in
serodiagnosis of acute M. pneumoniae infections. The use of short recombinant fragments of P116 and P1 proteins
as specific antigens may eliminate the risk of cross-reactions and help to develop a specific and sensitive
immunodiagnostic assay for M. pneumoniae detection.
Background
M. pneumoniae is among the most common causes of
community-acquired respiratory tract infection [1]. M.
pneumoniae causes upper and lower respiratory illness
in all age groups and accounts for 3.3-40% of commu-
nity-acquired pneumonia (CAP) cases worldwide with
an attack rates ranging from 25-71% among closed
populations. Approximately 25% of individuals infected
with M. pneumoniae develop extra-pulmonary complica-
tions [2].
M. pneumoniae infection is frequently seen in the
patients with respiratory illnesses [1]. Recently an
increased association of M. pneumoniae has been
reported in acute exacerbation of bronchial asthma and
chronic obstructive pulmonary disease (COPD) [3-5],
acute respiratory distress syndrome (ARDS) [6,7], poly-
arthritis [8], stroke [9], Guillain-Barre syndrome [10],
coronary artery diseases (CAD) [11,12] and increased
seroprevalence in HIV positive patients with respiratory
infections [13]. Therefore, presence of M. pneumoniae
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various respiratory and non-respiratory infections as the
pathogen respond well to antibiotics, such as tetracy-
clines, macrolides and quinolones [14].
Mycoplasmas are cell wall deficient, the smallest known
self-replicating organisms. They possess a small genome
(0.58-2.20 Mbp) [15]. M. pneumoniae possess an apical
organelle that mediates adherence to the host epithelium.
The cytadherence is a complex multifactorial process
requiring a group of proteins such as P1(170 kDa), P30(30
kDa), P116(116 kDa), HMW1-3 and proteins A, B and C.
These proteins cooperate structurally and functionally for
adherence as well as for the gliding mobility [16]. Among
these apical organelle associated proteins, P1 and P30 have
been previously shown by us and others to elicit immuno-
logical responses in human and are also involved in bind-
ing to host epithelial receptors [17-21]. In addition to
these proteins, a 116-kDa protein of M. pneumoniae was
identified as a membrane protein in triton-X-114 soluble
fraction of the pathogen and its gene was identified. P116
protein is encoded in an operon, consisting of a 3093 bp
ORF(orf 1030, Mpn number 213) encoding a protein of a
predicted molecular mass, 116 kDa and a 408 bp ORF(orf
135, Mpn number 212) that is predicted to code a 16 kDa
protein (5’-16 kDa ORF-116 kDa ORF-3’). Northern blot
analysis and RT-PCR amplification of the intergenic region
established that the ORFs encoding the 16 kDa and 116
kDa proteins are transcribed as a single mRNA. Swenstrup
and co-workers showed that the P116 protein is expressed
on the surface of M. pneumoniae and a polyclonal anti-
body Pab(rP116) inhibited the adherence of M. pneumo-
niae to Hep-2 cells [22]. These results demonstrated the
role of M. pneumoniae P116 in cytadherence, like the
other two adhesins P1 [23] and P30 [24]. A couple of stu-
dies have demonstrated the immune responses to the
P116 fragment [25]. Our group has been working on the
identification and characterization of the possible immu-
nodominant molecules of M. pneumoniae for their immu-
nodiagnostic potential. In the present study, we expressed
and purified an N-terminal fragment (203aa) of P116 pro-
tein and showed that the protein is well recognized by
sera of M. pneumoniae infected Indian patients. We next
compared the immunoreactivity of recombinant P116 and
P1 proteins with that of a commercially available ELISA
kit - the Serion ELISA classic IgM(Virion-Serion, GmbH,
Germany). Our results show that a short N-terminal frag-
ment (203aa) of P116 protein holds a promise for sero-
diagnosis of M. pneumoniae infection.
Methods
Study subjects and diagnosis
The study was carried out with the approval of the
Institute’s human & animal ethics committee (Ref. 51/
7.1.2004/AIIMS). Blood Samples were collected over a
period of two and a half years i.e Sep.05 through March
07 from 62 patients between 1 m to 70 yrs of age,
admitted in the wards and intensive care units of AIIMS
hospital. Each patient’s medical history was recorded in
a specific format and written informed consent was
obtained.
Commercially available Serion ELISA classic IgM
(Virion-Serion, GmbH, Germany) kit, which uses mix-
ture of undefined M. pneumoniae antigens, was used as
screening test as well as reference test for comparison.
This kit was selected, because of its availability and its
use in various studies [17,26,27].
Bacterial strains and culture conditions
M. pneumoniae standard strain FH (NCTC 10119), was
grown in Edward Hayflick medium containing PPLO
basal broth with supplements including glucose(1%;
Difco, USA) and phenol red (0.0002%) as indicator in
glass tubes. The culture was grown at 37°C, aerobically
until the colour of the medium changed (red-orange).
Mycoplasma cells were harvested at this stage by centri-
fugation at 15,000 rpm for 15 min, washed twice with
PBS (pH 7.2) and were stored at -70°C until use. To
confirm that the colour change of culture medium is
due to M. pneumoniae growth, the broth culture was
plated on PPLO agar plates and the plates were incu-
b a t e da t3 7 ° Ci naC O 2 incubator. The plates were
examined microscopically once in five days with X10
magnification. The suspected colonies were stained with
Diene’s stain and checked under light microscopy.
Further confirmation of the colonies was carried out by
growth inhibition assay using M. pneumoniae polyclonal
antisera (NCTC).
PCR amplification and cloning of P116-609 bp fragment
To clone 609 bp fragment of M. pneumoniae P116 gene
that codes for a protein of 203 amino acids, primers
were designed using published sequence (accession no.
Z71425) [28]. M. pneumoniae genomic DNA was
extracted as per the method of Stauffer et al [29]. Fol-
lowing set of primers with underlined introduced
restriction sites (Microsynth, Switzerland) were used for
the gene amplification:
The F1 was positioned at 786 nt whereas R1 at 1375
nt within the gene coding for P116 protein. PCR ampli-
fication was performed in a reaction volume of 50 μl
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5 0 0m MK C l ,1 5m MM g C l 2 and 0.1% gelatin), 200 μm
dNTP’s, 20 pmol of each primer, 1U Taq Polymerase
(5U/μl, MBI, Fermentas) and template DNA (50 ng) in a
GeneAMP PCR system 9700 (Applied Biosystems,
Switzerland). The PCR conditions were-initial denatura-
tion at 94°C for 5 min followed by 30 cycles of amplifi-
cation (each of 94°C for 30 s, 46°C for 30 s and 72°C for
1 min) with final extension at 72°C for 5 min. The PCR
product was analysed by 1% agarose gel electrophoresis
in 0.5% Tris-borate EDTA buffer and purified by gel
extraction kit (Qiagen, Germany).
Cloning and Expression of N-terminal fragment of P116
protein of M. pneumoniae in a prokaryotic expression
system
The purified P116 gene fragment was ligated into
pGEMT-easy vector and the ligation mixture was used
to transform DH5-a E. coli cells. Colonies were selected
on Luria Bertani (LB) agar plates containing 100 μg/ml
of ampicillin, 20 mg of X-gal and 200 mg/ml of IPTG
(Sigma-Aldrich, USA). The selected white colonies were
f u r t h e ra n a l y z e df o rt h ep r e s e n c eo fP 1 1 6g e n ef r a g -
ment. Recombinant plasmids were extracted using Mini-
prep plasmid extraction kit (Qiagen).
For the expression and purification of P116 protein
fragment, the 609 bp fragment was cloned in pQE-30
vector with Bam HI and Pst I restriction sites. The
ligated plasmid DNA was used to transform competent
M-15 cells. Transformants were selected on ampicillin
(100 μg/ml) and kanamycin (25 μg/ml) plate. M-15 cells
containing the recombinant plasmids were cultivated in
5 ml of LB broth and the protein expression was
induced by the addition of 1 mM IPTG final concentra-
tion, followed by 3 hrs of shaking at 37°C. Bacterial pel-
let was subjected to SDS-PAGE and western blotting
using anti-His antibody to analyze the expression of
recombinant protein.
SDS-PAGE and western blotting
To analyse the expression of the (P116(N-27)) recombi-
nant protein, induced and un-induced E. coli pellets
from 1 ml of grown cultures were resuspended in 100
μl of SDS sample buffer (62.5 mM Tris-HCl, pH 6.8,
10% glycerol, 2.3% w/v SDS, 5% v/v b-mercaptoethanol
and 0.05% w/v bromophenol blue) and boiled for 5 min.
T h ep r o t e i n sw e r er e s o l v e do n1 0 %S D S - P A G Eg e la n d
stained with Coomassie brilliant blue R-250. For immu-
noblotting, after separating proteins on gel, the resolved
proteins were transferred onto a nitrocellulose
membrane (Sigma-Aldrich) in a transblot apparatus
(Mini-PROTEAN III, Bio-Rad, USA). The membrane
was blocked in blocking buffer (5% skimmed milk in
PBS-T) for 2 h. The blots were washed and incubated
with anti-His primary antibody (1:10,000 dilution) or
anti-M. pneumoniae antibody (1:5,000 dilution) or sera
from M. pneumoniae infected patients (1:50) for 1 h.
Later the blots after washing, were incubated with sec-
ondary antibody (1:2000 dilution of anti-mouse, anti-
rabbit or with 1:5000 dilution of anti-human antibody
conjugated with horse-raddish peroxidase. The blots
then developed with 3, 3’-diaminobenzidine tetrabenzi-
dine hydrochloride (DAB)-H2O2 (Sigma-Aldrich).
Purification and Characterization of N-terminal fragment
of P116 protein
Sub-cellular localization studies were carried out to ana-
lyse the expression of P116 protein fragment in E. coli
cells and the protein was found to be expressed in inclu-
sion bodies. For the preparation of inclusion bodies E.
coli. cells were disrupted by sonication in buffer ((0.05
M Tris (pH 8.0), and 0.3 M NaCl) with 1-min pulses at
1-min intervals 10 times using mini probe (Torbeo,
ultrasonic processor 36800-series). The soluble and
insoluble fractions were separated by centrifugation at
1 4 , 0 0 0r p ma t4 ° Cf o r3 0m i na n dw e r ea n a l y z e db y
S D S - P A G E .T op u r i f yt h ep r otein from the inclusion
bodies, E. coli p e l l e tf r o m2 0 0m lo fc u l t u r ew a ss u s -
pended in 1/50 original volume of lysis buffer (0.05 M
Tris (pH 8.0), 0.3 M NaCl and 8 M Urea). The lysate
was loaded onto a Ni-NTA column (Qiagen) and the
bound protein was eluted under denaturing conditions
in a buffer containing 0.05 M Tris (pH 8.0), 0.3 M
NaCl, 0.3 M imidazole and 8 M Urea. The denatured
protein was refolded by dialysis using buffers containing
0.05 M Tris (pH 8.0), 0.3 M NaCl and decreasing con-
centrations of Urea, 6M-0.5M. The refolded protein was
stored in buffer containing 0.05 M Tris (pH 8.0), 0.15
M NaCl, 0.5 M Urea and 5% glycerol. Purified recombi-
nant P116 protein fragment (P116(N-27)) was analysed
for its reactivity with positive anti-M. pneumoniae
human sera in western blot assay.
Expression and purification of the C-terminal recombinant
P1 protein fragment P1(C-40) of M. pneumoniae
Expression and purification of P1 protein fragment was
carried out by a protocol described by Chaudhry et al
[17].
Immunization of Rabbits
The protein concentration of both the antigens prepara-
t i o nw a sd e t e r m i n e db yB r a d f o r da s s a y .T oc h e c kt h e
immunogenicity of the two recombinant proteins-P116
and P1, four White New Zealand rabbits (two tests and
two controls) were selected. Each one of the two test
rabbits was immunized with 300 μl (250 μg) of purified
recombinant P116(N-27) or P1(C-40) protein emulsified in
300 μl Complete Freund adjuvant (CFA, Sigma-Aldrich)
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boosted with 300 μl( 2 5 0μg) of the same protein in 300
μl Incomplete Freund adjuvant (IFA, Sigma-Aldrich),
through the same route on the 21
st and 42
nd days. Con-
trol rabbits were injected with complete and incomplete
Freund’s adjuvant in normal saline according to the
immunization schedule. Blood samples were obtained by
ear vein puncture on 0
th,1 4
th,2 1
st,2 8
th,3 5
th,4 9
th and
56
th days. IgM and IgG antibody responses against the
two purified recombinant proteins were analysed by
ELISA and end point titres were determined. In order
to confirm the specificity of the antisera western blot-
ting with whole M. pneumoniae as antigen was also
performed.
Comparative ELISA with purified recombinant P116(N-27),
P1(C-40) and commercial IgM assay
Sera obtained from sixty two patients suffering from
respiratory tract infections were analysed for the pre-
sence of anti-M. pneumoniae IgM antibody (which is an
indicator of the acute infection), using Serion ELISA kit.
Among the sixty two sera samples tested, thirty one
samples were found positive for the anti-M. pneumoniae
IgM antibodies. We next compared the antibody
response seen with Serion kit with the response seen
with recombinant P116(N-27),P 1 (C-40) or P116(N-27) +P 1
(C-40) together for IgM antibodies. The experiment was
done in duplicate. Briefly, 100 ng of P116(N-27) or P1(C-
40) was added to each well of 96-well microtiter plates.
In case of P116(N-27) +P 1 (C-40) assay, P116(N-27) and P1
(C-40) antigens were mixed in 1:1 ratio. The plates were
incubated overnight at 4°C and further for one hour at
37°C next day. The plates were washed with PBS-T and
blocked with 5% BSA in PBS for 2 h. The plates were
subsequently washed twicew i t hP B S - T ,o n c ew i t hP B S
and incubated with 1:50 diluted patient sera at 37°C for
1 h. The positive control (individual serum, tested posi-
tive by the commercial kit) and negative control (indivi-
dual serum, tested negative by the commercial kit) were
included in each ELISA assay and they were also diluted
t ot h es a m ee x t e n t .T h ew e l l sw e r ew a s h e da n di n c u -
bated with HRP-conjugated goat anti-human IgM
(Sigma-Aldrich) diluted 1:3000 in PBS-T, for 1 h. The
enzyme reaction was developed by the addition of the
substrate ortho-phenylenediamine (Sigma) (1 mg/ml)
diluted in phosphate-citrate buffer (pH 5.0) containing
0.03% (v/v) hydrogen peroxide. The enzymatic reaction
was stopped with 100 μlo f2 NH 2SO4 and absorbance
was read at 490nm with ELISA (Bio-Tek Microplate)
reader.
Statistical Analysis
Comparative statistical analysis of ELISA assays for
P116 and P1 proteins was done taking Serion IgM kit
(100% sensitive and 75% specific as per the manufac-
turer’s claim) as reference test. Analysis was performed
with the SPSS version 15.0(Chicago, USA). The para-
meters of in house ELISA assays were calculated by
using Epitable module of Epiinfo (6.04D) software.
Cohen’s Kappa test was used to find the agreement
between two different modalities. The chi-square test
of proportions was applied to compare two propor-
tions with the p value < 0.05 considered statistically
significant. Cut-off values were calculated by taking
median values of the controls.
Results
Cloning and Expression of N-terminal fragment of M.
pneumoniae P116 protein
A 609 bp fragment of P116 gene (786nt-1394nt) coding
for a protein of 203 amino acids was successfully ampli-
fied by PCR using the designed primers, and was cloned
into pGEM-T easy vector. Figure 1A shows the sche-
matic of P116 gene and the location of the amplified
gene fragment. The cloned fragment was sequenced
using an automated sequencer and its sequence was
similar to the published sequence of the P116 gene of
the strain FH [25] used in this study. To express the
P116 gene fragment, the PCR amplified fragment was
sub-cloned into pQE-30 vector and protein expression
was analysed on SDS-PAGE. Sub-cellular localization
studies showed that protein of mol. wt. of ~27 kDa was
mainly expressed in inclusion bodies (Figure 1B). The
expressed protein showed reactivity with anti-Penta. His
antibody (Figure 1C) as well as with the anti-M. pneu-
moniae antibody (data not shown).
P116(N-27) protein was purified under denaturing con-
ditions on a Ni-NTA column (Figure 2A). The yield of
the protein was ~5 mg/l. Fractions containing the dena-
tured proteins were pooled in a dialysis bag and the pro-
tein was dialysed in buffers, 0.05 M Tris (pH 8.0), 0.3 M
NaCl containing decreasing concentrations of Urea, 6M-
0.5M at 4°C. Some amount of protein got precipitated
after dialysis and the final yield of the refolded protein
was ~2 mg/l of the culture (Figure 2A).
Immunoblot analysis of recombinant P116(N-27) with M.
pneumoniae infected patient sera
Immunoblot analysis was carried out using rabbit anti-
M. pneumoniae s e r u m( F i g u r e2 B( i i )a n ds e r af r o mM.
pneumoniae infected patient (Figure 2B (iii). As shown
in Figure 2B, P116(N-27) was recognized by both the
sera strongly. This reactivity was specific as sera from
healthy humans (age matched persons without any his-
tory of the respiratory tract infections) failed to recog-
nize any such protein (Figure 2B(i)). We next analysed
the reactivity of recombinant P116(N-27) protein with
eleven sera from different patients infected with M.
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controls), for IgM antibody. All the eleven sera showed
reactivity with the P116(N-27) protein, while sera from
uninfected patients failed to recognize the P116(N-27).
These results suggested that the N-terminal region
(27 kDa) is one of the immunodominant region of the
P116 protein.
P116(N-27) and P1(C-40) proteins are immunogenic
To know whether the two proteins P116(N-27) and P1(C-
40) are immunogenic in nature, we formulated these
recombinant proteins with CFA and injected them in
rabbits. High antibody response was generated against
t h ec o r r e s p o n d i n gp r o t e i n .T h et i m ec o u r s eo ft h e
immune response for each of the recombinant proteins
(Figure 3A) showed that antibody titres gradually
increased after first and second boost and peaked after
the second boost. The end point titres for P116(N-27)
and P1(C-40) were > 2,56,000 for both the proteins.
Western blotting with whole M. pneumoniae as antigen
confirmed the specificity of t h ea n t i s e r ar a i s e da st h e y
recognized single specific bands for each antigen with-
out any cross-reactivity (Figure 3B &3C).
Comparative ELISA analysis
A comparative evaluation of the reactivity of the patient
sera with P116(N-27) and P1(C-40) proteins along with
Serion (Virion-Serion, GmbH, Germany) kit was carried
out to determine immunodiagnostic potential of these
recombinant antigens in immunodiagnosis of M. pneu-
moniae infections. A total of 62 sera were analysed for
their reactivity to the recombinant proteins individually
and together in ELISA assays. In the beginning, these
sera were also tested with the commercial Serion kit
and thirty one sera were found positive for IgM antibo-
dies to M. pneumoniae. Although most patient sera
shown to be positive for M. pneumoniae antibodies by
Serion kit were also positive for their reactivity towards
P116(N-27) and P1(C-40) proteins, however few differences
were also observed. Of the 31 positive sera selected
based on the reactivity with commercial kit, 28, 27 and
30 sera reacted with P116(N-27) and P1(C-40), and P116(N-
P116(N-27)
B
Į-Penta.His
3       2       1
C
P116(N-27)
85
45
36
26
20
kDa
F1( 786) R1(1375)
762                                                              3854
Figure 1 Cloning and Expression of N-terminal fragment (203aa) of P116 protein of M. pneumoniae. A: Schematic diagram showing P116
gene sequence and location of fragment of P116 gene selected for cloning and expression. Fig. also shows positions of F1 (forward) and R1
(reverse) primers within the gene coding for P116 protein. B: SDS-PAGE analysis of N-terminal P116 protein showing its expression in E. coli and
its subcellular localization. Lane1: Prestained standard protein marker, Lane 2: Protein extracts of uninduced E. coli, Lane 3: Protein extracts of
induced (~27 KDa) E. coli, Lanes 4&5: E. coli pellets of the expressed protein after sonication, Lanes 6&7: Supernatant after sonication. C:
Immunoblot analysis of crude P116 protein with anti. His antibodies-Lane1: Prestained standard protein marker, Lane 2: Protein extracts of
uninduced E. coli, Lane 3: Recombinant protein detected with anti. His antibodies.
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sponding respiratory samples for eleven of the sixty two
sera were also positive by the PCR for 543 bp fragment
of M. pneumoniae P1 gene.
Interestingly, four out of 31 seronegative patients as
determined by Serion kit showed reactivity with the
P116(N-27) protein or P116(N-27) and P1(C-40) combined
(Figure 5). Western blot analysis for these four cases
further confirmed the reactivity of three of the four sera
with P116(N-27) protein. Western blot could not be per-
formed for one serum sample due to its inadequate
volume. Among the seropositive group, 3 sera were
negative by P116(N-27) based ELISA. Of these 3, one was
also negative by P1(C-40) based assay. However, all these
3s e r aw e r ep o s i t i v ei nP 1 1 6 (N-27) +P 1 (C-40) based
ELISA.
Statistical analysis
A comparative analysis of the P116(N-27), P1(C-40),P 1 1 6
(N-27) +P 1 (C-40) ELISA and assay with Serion kit (the
reference test), was done (Table 1). The cut off value
was taken as an absorbance 0.3. At 0.3 absorbance, the
senstivity and specificity was 90.3% and 87.0% for P116
(N-27), 87.1% and 87.1% for P1(C-40), and 96.8% and
90.3% for (P116(N-27) +P 1 (C-40)) respectively. The
p value for all the three assays was found to be < 0.001,
w h i c hi sh i g h l ys i g n i f i c a n ta n dt h e r ew a sag o o d
correlation and association between them. There was
an observed agreement of 77.4% and 74% between
P116(N-27), P1(C-40) and commercial ELISA respectively
and is the highest (87%) between the P116(N-27) +
P1(C-40) combined ELISA and commercial ELISA.
Discussion
Laboratory investigations are important in the diagnosis
of M. pneumoniae infections, as it is often difficult to
differentiate different etiological agents by clinical symp-
toms. Even though a number of clinical tests such as
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Figure 3 Immunogenicity and specificity of P116(N-27) and P1(C-
40) proteins and their antibodies. A. Bar diagram showing
Immune response in two different White NewZealand rabbits
immunized with purified recombinant P116(N-27) and P1(C-40)
proteins. Control rabbits were injected with complete and
incomplete Freund’s adjuvant in normal saline according to the
immunization schedule. B. Immunoblot analysis of M. pneumoniae
lysate showing reactivity of P1(179 kDa) with anti-P1 serum raised in
rabbit-Lane1: M. pneumoniae lysate, Lane 2: Blank, Lane 3: Prestained
standard protein marker. C. Immunoblot analysis of M. pneumoniae
lysate showing reactivity of P116(116 kDa) with anti-P116 serum
raised in rabbit-Lane 1: Prestained standard protein marker, Lane 2:
Blank, Lane 3: M. pneumoniae lysate
1          2         3        4          5       6         7         8
P116(N-27)
36
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C
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(ii)Į-M. 
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pneumoniae
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Figure 2 Purification and Characterization of N-terminal
fragment of P116 protein. A: SDS-PAGE analysis showing
purification of N-terminal P116 (P116(N-27)) protein on Ni-NTA
column. Lane 1: Prestained standard protein marker, Lane 2: Protein
extracts of uninduced E. coli, Lane 3: Protein extracts of induced
(~27 KDa) E. coli, Lane 4: Flow through, Lanes 5&6: Wash1 & Wash2,
Lane 7: Purified P116 protein before dialysis (eluted with buffer
containing 8M Urea), Lane 8: Purified P116 protein after dialysis
against buffer containing 0.5M Urea. B: Immunoblot analysis of
purified P116(N-27) protein with-(i) Healthy control human serum-
Lane 1: Prestained standard protein marker, Lane 2: Protein extracts
of uninduced E. coli, Lane 3: Recombinant protein detected with
representative healthy human serum. (ii) M. pneumoniae antibodies-
Lane 1: Recombinant protein detected using rabbit anti-M.
pneumoniae serum Lane 2: Protein extracts of uninduced E. coli,
Lane 3: Prestained standard protein marker. (iii) M. pneumoniae
infected patient sera-Lanes 1&2: Recombinant protein detected
using M. pneumoniae infected patient sera, Lane 3: Protein extracts
of uninduced E. coli, Lane 4: Prestained standard protein marker. C:
Immunoblot analysis of purified P116(N-27) protein with patient sera
infected with M. pneumoniae PM: Prestained standard protein
marker, NC: Negative control (patient sample which tested negative
with the reference test) and PC: positive control (patient sample
which tested positive with the reference test), Lanes 1-11: patient
sera infected with M. pneumoniae.
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M. pneumoniae infections, serology is probably the most
frequently used method to diagnose M. pneumoniae
infections as PCR based tests are expensive and require
specialized equipment [28]. Serological testing is often
hampered by inter-species cross-reactions and even non-
specific reactions [30] as the currently available serologi-
cal tests are based on crude cellular fractions of M. pneu-
moniae. An ELISA employing purified M. pneumoniae
surface proteins would be having inherent advantage of
specificity. One of the major difficulties of developing
serological test for the detection of M. pneumoniae is the
d i f f i c u l t yt oe x p r e s si t sp r o t e i n si nh e t e r o l o g o u se x p r e s -
sion system as the Mycoplasmas use the UGA opal
codon to incorporate tryptophan rather than as a stop
codon as in the universal genetic code [31], leading to
premature termination of the protein synthesis.
Although, a few reports from the western world are avail-
able, no study has been done in the Indian population,
which investigates the immunodiagnostic potential of the
M. pneumoniae 116-kDa virulence factor (P116). We
have been systematically analysing the serodiagnostic
potential of various surface adhesion antigens of M.
pneumoniae a n dp r e v i o u s l ys h o w e dt h a taC - t e r m i n a l
fragment of P1 and P30 protein hold potential to be used
for the diagnosis of M. pneumoniae infections [17,19].
In furtherance to these studies, we expressed an N-term-
inal fragment of P116 protein [28] using an E. coli
Figure 5 Comparative ELISA analysis of recombinant proteins with commercial assay with patient sera negative for M. pneumoniae
infection. Comparative ELISA analysis of purified recombinant P116(N-27),P 1 (C-40) and P116(N-27) +P 1 (C-40) with commercial ELISA for IgM
antibodies to M. pneumoniae with 31 negative patient sera. For each serum the “blue square” shows reactivity with the P116(N-27), whereas
“purple, yellow and green squares” show reactivity with the P1(C-40), P116(N-27) +P 1 (C-40) and commercial ELISA kit respectively (Inset shows
western blot results for the three patients negative by commercial ELISA, but positive in P116(N-27),o rP 1 (C-40) or P116(N-27)+P 1 (C-40) ELISAs as well
as in western blot with P116(N-27)).
Figure 4 Comparative ELISA analysis of recombinant proteins with commercial assay with patient sera infected with M. Pneumoniae.
Comparative ELISA analysis of purified recombinant P116(N-27),P 1 (C-40) and P116(N-27) +P 1 (C-40) with commercial ELISA for IgM antibodies to M.
pneumoniae with 31 positive patient sera. For each serum the “blue square” shows reactivity with the P116(N-27), whereas “purple, yellow and
green squares” show reactivity with the P1(C-40), P116(N-27) +P 1 (C-40) and commercial ELISA kit respectively.
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Page 7 of 9expression system with an N-terminal 6His-tag. The
expressed protein was ~27 kDa in size and was purified on
a Ni-NTA column under denaturation conditions. The
yield of the protein was ~5 mg/l. A simple refolding proto-
col was developed to get the protein in soluble form. Even
though the protein was expressed in inclusion bodies, a
significant yield of the protein after refolding (~2 mg/l)
could be obtained. The refolded soluble protein was recog-
nized by anti-M. pneumoniae antibodies, by most of the
M. pneumoniae infected patient sera and also by experi-
mentally infected rabbit sera by immunoblot analysis. Our
results were in agreement with a previous lone study by
Duffy et al who expressed GST fusion protein fragments
of P116 protein and showed that a 53 kDa P116 protein
fragment (pGEX-3X-MP661) encompassing 9aa-474aa
was recognized by most of the patient sera in ELISA [28].
The P116 fragment expressed in this study represented a
segment of pGEX-3X-MP661 protein and was also
expressed without a long fusion tag GST. The recombi-
nant P116(N-27) was also found to be immunogenic in rab-
b i t .T h eg e n es e q u e n c eo ft h eP 1 1 6 (N-27) fragment was
found similar to the sequence of P116 gene of M. pneumo-
niae s t r a i n sF Ha n dM - 1 2 9g i v e ni nt h ed a t a b a s e .T h e
nucleotide sequence of the gene encoding the 116 kDa
protein, and consequently also the epitopes of the protein,
is highly conserved between M. pneumoniae M-129 and
FH [28], which are representatives of the two M. pneumo-
niae groups. To know about the serodiagnostic potential
of P116(N-27) IgM ELISA, sixty two Indian patients suffer-
ing with M. pneumoniae infections were analyzed. All
these patients sera were also analyzed by the commercially
available Serion (Virion-Serion, GmbH, Germany) kit. In
comparison to the reference kit, which is reported to be
100% sensitive and 75% specific, ELISA assay based on
purified P116(N-27), P1(C-40) and (P116(N-27) +P 1 (C-40))p r o -
teins showed 90.3%, 87.1% and 96.8% sensitivity and
87.0%, 87.1% and 90.3% specificity respectively. The p
v a l u ef o ra l lt h et h r e ea s s a y sw a sf o u n dt ob e<0 . 0 0 1 ,
which is highly significant and there was a good correla-
tion and association between them. Our results also
demonstrated that an ELISA assay based on two recombi-
nant proteins was more sensitive and specific. During the
course of this study, a report by Drasbek et al described
the utility of P116 and P1 recombinant fragments for cor-
rect diagnosis of atypical pneumonia caused by M. pneu-
moniae [32]. The difference between these two studies is
that we used shorter fragments of P116 and P1 proteins to
take care of the specificity problems. We could achieve
moderate level of expression for both these recombinant
proteins (2-4 mg/l of culture) in the present study. One of
the major requirements with regard to the development of
an ELISA test for detecting M. pneumoniae infection is to
avoid possible cross-reactions with antibodies to M. geni-
talium [33]. To overcome this cross-reactivity, use of syn-
thetic peptides has been tried instead of whole protein
preparations [34]. We could not found significant
sequence similarity when we aligned the sequence of P116
(N-27) protein of M. pneumoniae with M. genitalium.T h u s ,
our study using the short recombinant fragment of P116
and P1 proteins together is an important step towards
developing M. pneumoniae specific and sensitive diagnos-
tic assay. Importantly, since present study was conducted
in a geographically distinct location than the study by
Drasbek et al, the study provides an important confirma-
tion of the global applicability of the findings of Drasbek
et al. Together these limited trials also indicate that
recombinant P116 and P1 proteins can be useful as sero-
diagnostic agents.
Conclusions
The present study describes a simplified approach for the
large-scale production of an immunodominant fragment
of P116 protein of M. pneumoniae. The report further
describes the immunodiagnostic potential of P116 and P1
proteins individually or combined by ELISA on parallel
patient’s serum samples. Since both protein fragments are
also immunogenic, it will be worth-while also to look for
vaccine potential of these recombinant proteins. Surveil-
lance or reporting system for M. pneumoniae infections
eg. positive serological results for M. pneumoniae based
on rapid and specific diagnostic tests, would be useful for
physicians in understanding the regional epidemiology of
M. pneumoniae infections, and also decide the empirical
antibiotic treatment to be used in these cases.
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